Menu

Estrella Immunopharma, Inc. ESLAW

Full chart Compare
Set alert

Price alert · ESLAW

All alert types
0.08 USD 0.00 (+0.00%)

Nov 2, 2026, 10:56 AM EST

0.0799 Day range 0.08
0.0799 52-week range 0.08
YTD
0.00%
1 year
0.00%
Market cap
25.37M
YTD return
0.00%
1-year return
0.00%
Volume
1.28K
Open
0.11
Previous close
0.0799
Day's range
0.0799 – 0.08
52-week range
0.0799 – 0.08
Beta
-0.09

2Y 0.0000 (0.00%)

No chart data for this range yet.

Key statistics

Enterprise value
0
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
2.81M
Total cash
2.48M
Total debt
22.00K
Return on equity
0.00%
Short % of float
0.00%
50-day average
0.00
200-day average
0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on ESLAW — it syncs with the Stock Master app.

Institution ownership

ESLAW institution ownership
Holder% heldSharesValueReported
Highbridge Capital Management, LLC.20.82%416,49538.27KSep 29, 2024
Boothbay Fund Management, LLC9.49%189,89917.45KSep 29, 2024
ATW Spac Management LLC9.15%183,09916.83KSep 29, 2024
Shaw D.E. & Co., Inc.4.38%87,5008.04KSep 29, 2024
Walleye Capital LLC3.31%66,1126.08KSep 29, 2024
SkyView Investment Advisors, LLC3.13%62,5005.74KSep 29, 2024

Fund ownership

ESLAW fund ownership
Holder% heldSharesValueReported
Investment Managers Ser Tr-Robinson Opportunistic Income Fd0.59%11,8051.08KSep 29, 2024